Perception Neuroscience

Clinical-stage biopharma company atai Life Sciences (NASDAQ: ATAI) shared results from majority-owned subsidiary Perception Neuroscience’s Phase 1 intravenous-to-subcutaneous bridging study of its proprietary R-ketamine compound PCN-101. See Also: Breaking Ground In Prevention &...

Clinical-stage psychedelics biotech atai Life Sciences (NASDAQ: ATAI) shared the results of its NYC-based subsidiary NYC-based Perception Neuroscience’s Phase 2a study of proprietary R-ketamine PCN-101 on patients with Treatment-Resistant Depression (TRD.). The company stated that while the...

Clinical stage psychedelics company atai Life Sciences (NASDAQ: ATAI) and its majority-owned subsidiary Perception Neuroscience completed patient enrollment for their Phase 2a clinical trial assessing the safety and efficacy of a single intravenous infusion (IV) dose of proprietary R-...

Perception Neuroscience, an Atai Life Sciences (NASDAQ: ATAI) subsidiary, is starting a Phase 2a clinical trial on PCN-101, its lead drug candidate. The study will evaluate the safety and efficacy of a proprietary formulation of arketamine that could have a similar therapeutic action to ketamine in...

Novamind Strikes Research Deal With Merck Psychedelics company Novamind (PINK: NVMDF) announced a subsidiary has been selected as a research site for a clinical trial of a compound developed by pharma giant Merck (NYSE: MRK). The phase II trial will assess the efficacy and safety of MK-1942,...

Novamind Raises CA$10M, Heads Towards CSE Listing Toronto-based psychedelics company Novamind Ventures announced the closing of a private placement for CA$10 million ($7.6 million). Last week, the company confirmed that it successfully inked a definitive amalgamation agreement with Hinterland...